Evicenter
P&T meetings

RP-A501 (AAV9.LAMP2B)

Danon disease

Regulatory submission
BLA planned for late 2028
Last updated
300 sources

Section 6 of 6

References

300 sources

  1. Adamou (2026) (opens in a new tab)
  2. Adler et al. (2019) (opens in a new tab)
  3. Al-Khatib et al. (2018) (opens in a new tab)
  4. Alcalai et al. (2021) (opens in a new tab)
  5. Alexion Soliris prescribing information (2026) (opens in a new tab)
  6. Apellis Empaveli prescribing information (2025) (opens in a new tab)
  7. Arad et al. (2005) (opens in a new tab)
  8. Arad et al. (2026) (opens in a new tab)
  9. Arbelo et al. (2023) (opens in a new tab)
  10. Argirò and Olivotto (2026) (opens in a new tab)
  11. Argiro et al. (2024) (opens in a new tab)
  12. Baskar et al. (2018) (opens in a new tab)
  13. Beinfeld et al. (2023) (opens in a new tab)
  14. bluebird bio Form 8-K (2022) (opens in a new tab)
  15. bluebird bio Form 8-K (2023) (opens in a new tab)
  16. bluebird bio ZYNTEGLO launch press release (2022) (opens in a new tab)
  17. Boespflug-Tanguy et al. (2026) (opens in a new tab)
  18. Boslough et al. (2026) (opens in a new tab)
  19. Bottillo et al. (2016) (opens in a new tab)
  20. Boucek et al. (2011) (opens in a new tab)
  21. Boucek et al. (2011) (opens in a new tab)
  22. Brambatti et al. (2019) (opens in a new tab)
  23. Briasoulis et al. (2018) (opens in a new tab)
  24. Brooks et al. (2020) (opens in a new tab)
  25. Bui et al. (2019) (opens in a new tab)
  26. Bui et al. (2021) (opens in a new tab)
  27. Byrne et al. (2025) (opens in a new tab)
  28. California Institute for Regenerative Medicine grant TRAN1-15230 (opens in a new tab)
  29. Catchpool et al. (2019) (opens in a new tab)
  30. CDC ICD-10 Coordination and Maintenance Committee (2022) (opens in a new tab)
  31. CDC National Center for Health Statistics ICD-10-CM (2026) (opens in a new tab)
  32. Cenacchi et al. (2020) (opens in a new tab)
  33. Chand et al. (2021) (opens in a new tab)
  34. Charron et al. (2004) (opens in a new tab)
  35. Chaudhary and Singh (2025) (opens in a new tab)
  36. Chen et al. (2012) (opens in a new tab)
  37. Chen et al. (2022a) (opens in a new tab)
  38. Chen et al. (2022b) (opens in a new tab)
  39. Cheng and Fang (2012b) (opens in a new tab)
  40. Cheng et al. (2012a) (opens in a new tab)
  41. Chhabra et al. (2024) (opens in a new tab)
  42. Chi et al. (2019) (opens in a new tab)
  43. ClinGen Actionability Working Group Danon disease summary report (2023) (opens in a new tab)
  44. ClinicalTrials.gov NCT03882437 (opens in a new tab)
  45. ClinicalTrials.gov NCT05548855 (opens in a new tab)
  46. ClinicalTrials.gov NCT06092034 (opens in a new tab)
  47. ClinicalTrials.gov NCT06214507 (opens in a new tab)
  48. CMS Cell and Gene Therapy Access Model (opens in a new tab)
  49. CMS Hospital Readmissions Reduction Program (opens in a new tab)
  50. CMS Medicare 2026 Part C and D Star Ratings Technical Notes (2025) (opens in a new tab)
  51. CMS Quality ID 005 measure specification (2025) (opens in a new tab)
  52. CMS Quality ID 008 measure specification (2025) (opens in a new tab)
  53. Colvin et al. (2025) (opens in a new tab)
  54. CSL Behring HEMGENIX prescribing information (2026) (opens in a new tab)
  55. CTIS.eu 2023-506480-34-00 (opens in a new tab)
  56. D'souza et al. (2014) (opens in a new tab)
  57. Danon Foundation (opens in a new tab)
  58. Darden et al. (2021) (opens in a new tab)
  59. Day et al. (2021) (opens in a new tab)
  60. Del Favero et al. (2020) (opens in a new tab)
  61. Dellefave-Castillo et al. (2022) (opens in a new tab)
  62. Demirdas et al. (2019) (opens in a new tab)
  63. Di Nora et al. (2020) (opens in a new tab)
  64. Dvornikov et al. (2019) (opens in a new tab)
  65. Echaniz-Laguna et al. (2006) (opens in a new tab)
  66. EMA list of medicines in the PRIME scheme (2026) (opens in a new tab)
  67. EMA orphan designation EU/3/23/2826 (2023) (opens in a new tab)
  68. EMA orphan designation EU/3/25/3062 (2025) (opens in a new tab)
  69. EMA paediatric investigation plan decision P/0004/2025 (2025) (opens in a new tab)
  70. EMA paediatric investigation plan EMEA-003639-PIP01-24 (2025) (opens in a new tab)
  71. EMA scientific recommendations on classification of advanced therapy medicinal products (2026) (opens in a new tab)
  72. Emfietzoglou et al. (2026) (opens in a new tab)
  73. Endo et al. (2015) (opens in a new tab)
  74. EU CTIS 2023-506480-34-00 (opens in a new tab)
  75. EU CTIS 2023-506480-34-00 (opens in a new tab)
  76. Fanin et al. (2006) (opens in a new tab)
  77. FDA Cellular, Tissue, and Gene Therapies Advisory Committee briefing document (2021) (opens in a new tab)
  78. FDA Elevidys safety communication (2025) (opens in a new tab)
  79. FDA expedited programs for regenerative medicine therapies guidance (2019) (opens in a new tab)
  80. FDA long term follow-up after gene therapy guidance (2020) (opens in a new tab)
  81. FDA Orphan Drug Designations and Approvals (2019) (opens in a new tab)
  82. FDA rare pediatric disease priority review voucher program (2026) (opens in a new tab)
  83. Fernández et al. (2021) (opens in a new tab)
  84. Florida Agency for Health Care Administration Independent Laboratory Fee Schedule (2026) (opens in a new tab)
  85. Flotte (2026) (opens in a new tab)
  86. Fu et al. (2016) (opens in a new tab)
  87. Gandaeva et al. (2023) (opens in a new tab)
  88. Genentech Rituxan prescribing information (2021) (opens in a new tab)
  89. Godown et al. (2018a) (opens in a new tab)
  90. Godown et al. (2018b) (opens in a new tab)
  91. Greenberg et al. (2021) (opens in a new tab)
  92. Greenberg et al. (2022) (opens in a new tab)
  93. Greenberg et al. (2025) (opens in a new tab)
  94. Grisorio et al. (2024) (opens in a new tab)
  95. Guillou et al. (2022) (opens in a new tab)
  96. Gunes et al. (2025) (opens in a new tab)
  97. Guo et al. (2019) (opens in a new tab)
  98. Gurka et al. (2020) (opens in a new tab)
  99. Hashem et al. (2015) (opens in a new tab)
  100. Hashem et al. (2017) (opens in a new tab)
  101. Hashida et al. (2015) (opens in a new tab)
  102. Health Research Authority research summary (2024) (opens in a new tab)
  103. Hedberg Oldfors et al. (2015) (opens in a new tab)
  104. Heidenreich et al. (2020) (opens in a new tab)
  105. Heidenreich et al. (2022) (opens in a new tab)
  106. Hershberger et al. (2018) (opens in a new tab)
  107. Hinderer et al. (2018) (opens in a new tab)
  108. Hong et al. (2022) (opens in a new tab)
  109. Hong et al. (2023a) (opens in a new tab)
  110. Hong et al. (2023a) (opens in a new tab)
  111. Hong et al. (2023b) (opens in a new tab)
  112. Hong et al. (2025) (opens in a new tab)
  113. Horizon Pharma Rayos prescribing information (2012) (opens in a new tab)
  114. HRSA OPTN transplant program performance monitoring (opens in a new tab)
  115. Hummel et al. (2020) (opens in a new tab)
  116. Hypertrophic Cardiomyopathy Association (2026) (opens in a new tab)
  117. ICD10Data.com (2026) (opens in a new tab)
  118. ICER single and short-term therapies methods (2022) (opens in a new tab)
  119. ICER Zolgensma approval statement (2019) (opens in a new tab)
  120. Ingles et al. (2012) (opens in a new tab)
  121. Ingles et al. (2019) (opens in a new tab)
  122. Inoue et al. (2024) (opens in a new tab)
  123. Invitae Cardiomyopathy Comprehensive Panel test catalog (opens in a new tab)
  124. Invitae Danon disease sponsored testing program (opens in a new tab)
  125. Jackson et al. (2018) (opens in a new tab)
  126. Jain et al. (2021) (opens in a new tab)
  127. Jeong et al. (2025) (opens in a new tab)
  128. Jhaveri et al. (2019) (opens in a new tab)
  129. Kartal Allen (2025) (opens in a new tab)
  130. Keravala et al. (2019) (opens in a new tab)
  131. Khedro et al. (2025) (opens in a new tab)
  132. Kitahara et al. (2017) (opens in a new tab)
  133. Kittleson et al. (2024) (opens in a new tab)
  134. Konrad et al. (2017) (opens in a new tab)
  135. Kousal et al. (2021) (opens in a new tab)
  136. Kuroda et al. (2019) (opens in a new tab)
  137. Laforet (2025) (opens in a new tab)
  138. Law et al. (2012) (opens in a new tab)
  139. Lee et al. (2026) (opens in a new tab)
  140. Lek et al. (2023) (opens in a new tab)
  141. Limongelli et al. (2022) (opens in a new tab)
  142. Lipshultz et al. (2019) (opens in a new tab)
  143. Liu et al. (2017) (opens in a new tab)
  144. Liu et al. (2018) (opens in a new tab)
  145. Liu et al. (2019) (opens in a new tab)
  146. Liu et al. (2026) (opens in a new tab)
  147. López-Sainz et al. (2019) (opens in a new tab)
  148. Lotan et al. (2020) (opens in a new tab)
  149. Lotan et al. (2020) (opens in a new tab)
  150. Ma et al. (2018) (opens in a new tab)
  151. Ma et al. (2019) (opens in a new tab)
  152. Mahle et al. (2008) (opens in a new tab)
  153. Majer et al. (2014) (opens in a new tab)
  154. Majer et al. (2018) (opens in a new tab)
  155. Managed Healthcare Executive (2025) (opens in a new tab)
  156. Managed Healthcare Executive (2026) (opens in a new tab)
  157. Manso et al. (2020) (opens in a new tab)
  158. Margolin et al. (2022) (opens in a new tab)
  159. Maron et al. (2009) (opens in a new tab)
  160. Maron et al. (2025) (opens in a new tab)
  161. Marras et al. (2008) (opens in a new tab)
  162. Maurizi et al. (2025) (opens in a new tab)
  163. Maurizi et al. (2026a) (opens in a new tab)
  164. Maurizi et al. (2026b) (opens in a new tab)
  165. McNally and Spencer (2025) (opens in a new tab)
  166. MedlinePlus Genetics (2024) (opens in a new tab)
  167. Mehra et al. (2016) (opens in a new tab)
  168. Miani et al. (2012) (opens in a new tab)
  169. Milliman (2025) (opens in a new tab)
  170. Musunuru et al. (2020) (opens in a new tab)
  171. Naddaf (2022) (opens in a new tab)
  172. Nandi et al. (2016) (opens in a new tab)
  173. NCQA CRE measure page (opens in a new tab)
  174. NCQA PCR measure page (opens in a new tab)
  175. Nishino et al. (2000) (opens in a new tab)
  176. Novartis Zolgensma access programs press release (2019) (opens in a new tab)
  177. Novartis ZOLGENSMA prescribing information (2026) (opens in a new tab)
  178. Odouard et al. (2024) (opens in a new tab)
  179. Oktay et al. (2023) (opens in a new tab)
  180. Olivotto et al. (2008) (opens in a new tab)
  181. OMIM 300257 (opens in a new tab)
  182. Ommen et al. (2024) (opens in a new tab)
  183. Orbach et al. (2026) (opens in a new tab)
  184. Orchard Therapeutics (2024) (opens in a new tab)
  185. Oren et al. (2019) (opens in a new tab)
  186. Orphanet (2024) (opens in a new tab)
  187. Osenenko et al. (2022) (opens in a new tab)
  188. Pagliarulo (2025) (opens in a new tab)
  189. Papillon Therapeutics (2024) (opens in a new tab)
  190. Parajuli et al. (2026) (opens in a new tab)
  191. Patel et al. (2018) (opens in a new tab)
  192. Pearson et al. (2019) (opens in a new tab)
  193. Pelc et al. (2026) (opens in a new tab)
  194. Peled et al. (2024) (opens in a new tab)
  195. Pfizer Rapamune prescribing information (2019) (opens in a new tab)
  196. Philippidis (2025) (opens in a new tab)
  197. Poignant et al. (2017) (opens in a new tab)
  198. Power et al. (2024) (opens in a new tab)
  199. Prall et al. (2006) (opens in a new tab)
  200. Ribeiro et al. (2026) (opens in a new tab)
  201. Richards et al. (2026) (opens in a new tab)
  202. Rigolli et al. (2020) (opens in a new tab)
  203. Rigolli et al. (2021) (opens in a new tab)
  204. Rocket Pharmaceuticals and REGENXBIO license announcement (2018) (opens in a new tab)
  205. Rocket Pharmaceuticals clinical hold lift announcement (2021) (opens in a new tab)
  206. Rocket Pharmaceuticals clinical hold lift announcement (2025) (opens in a new tab)
  207. Rocket Pharmaceuticals clinical safety update announcement (2026) (opens in a new tab)
  208. Rocket Pharmaceuticals corporate presentation (2023) (opens in a new tab)
  209. Rocket Pharmaceuticals credit facility announcement (2026) (opens in a new tab)
  210. Rocket Pharmaceuticals Danon disease clinical trials page (opens in a new tab)
  211. Rocket Pharmaceuticals Danon disease program update presentation (2023) (opens in a new tab)
  212. Rocket Pharmaceuticals Danon disease program update presentation (2026) (opens in a new tab)
  213. Rocket Pharmaceuticals end-of-phase 1 meeting announcement (2022) (opens in a new tab)
  214. Rocket Pharmaceuticals enrollment completion announcement (2024) (opens in a new tab)
  215. Rocket Pharmaceuticals expanded access policy (opens in a new tab)
  216. Rocket Pharmaceuticals FDA alignment announcement (2026) (opens in a new tab)
  217. Rocket Pharmaceuticals first quarter 2021 results announcement (2021) (opens in a new tab)
  218. Rocket Pharmaceuticals first quarter 2026 results announcement (2026) (opens in a new tab)
  219. Rocket Pharmaceuticals Form 10-K (2020) (opens in a new tab)
  220. Rocket Pharmaceuticals Form 10-K (2023) (opens in a new tab)
  221. Rocket Pharmaceuticals Form 10-K (2025) (opens in a new tab)
  222. Rocket Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  223. Rocket Pharmaceuticals Form 10-Q (2021) (opens in a new tab)
  224. Rocket Pharmaceuticals Form 10-Q (2026) (opens in a new tab)
  225. Rocket Pharmaceuticals Form 8-K (2020) (opens in a new tab)
  226. Rocket Pharmaceuticals Form 8-K (2022) (opens in a new tab)
  227. Rocket Pharmaceuticals Form 8-K (2024) (opens in a new tab)
  228. Rocket Pharmaceuticals Form 8-K (2026) (opens in a new tab)
  229. Rocket Pharmaceuticals IND clearance announcement (2019) (opens in a new tab)
  230. Rocket Pharmaceuticals investor presentation (2024) (opens in a new tab)
  231. Rocket Pharmaceuticals investor webinar announcement (2026) (opens in a new tab)
  232. Rocket Pharmaceuticals LAMPLIGHT Studies website (opens in a new tab)
  233. Rocket Pharmaceuticals phase 1 interim results presentation (2020) (opens in a new tab)
  234. Rocket Pharmaceuticals phase 1 update announcement (2021) (opens in a new tab)
  235. Rocket Pharmaceuticals phase 1 update presentation (2021) (opens in a new tab)
  236. Rocket Pharmaceuticals phase 1 update presentation (2022) (opens in a new tab)
  237. Rocket Pharmaceuticals phase 2 trial update announcement (2025) (opens in a new tab)
  238. Rocket Pharmaceuticals pivotal trial design announcement (2023) (opens in a new tab)
  239. Rocket Pharmaceuticals preclinical data announcement (2019) (opens in a new tab)
  240. Rocket Pharmaceuticals PRIME designation announcement (2023) (opens in a new tab)
  241. Rocket Pharmaceuticals reorganization announcement (2025) (opens in a new tab)
  242. Rocket Pharmaceuticals RMAT designation announcement (2023) (opens in a new tab)
  243. Rocket Pharmaceuticals second quarter 2021 results announcement (2021) (opens in a new tab)
  244. Rocket Pharmaceuticals second quarter 2026 results announcement (2026) (opens in a new tab)
  245. Rocket Pharmaceuticals third quarter 2024 results announcement (2024) (opens in a new tab)
  246. Rocket Pharmaceuticals third quarter 2025 results announcement (2025) (opens in a new tab)
  247. Rossano et al. (2012) (opens in a new tab)
  248. Rossano et al. (2022a) (opens in a new tab)
  249. Rossano et al. (2022b) (opens in a new tab)
  250. Rossano et al. (2023a) (opens in a new tab)
  251. Rossano et al. (2023b) (opens in a new tab)
  252. Rowland et al. (2016) (opens in a new tab)
  253. Rubin et al. (2025) (opens in a new tab)
  254. Salabarria et al. (2024) (opens in a new tab)
  255. Salisbury and Meredith (2019) (opens in a new tab)
  256. Samad et al. (2017) (opens in a new tab)
  257. Sarepta Therapeutics ELEVIDYS approval presentation (2023) (opens in a new tab)
  258. Sarepta Therapeutics ELEVIDYS prescribing information (2026) (opens in a new tab)
  259. Shah et al. (2016) (opens in a new tab)
  260. Shah et al. (2021) (opens in a new tab)
  261. Shieh et al. (2026) (opens in a new tab)
  262. Sikora et al. (2015) (opens in a new tab)
  263. Silver et al. (2026a) (opens in a new tab)
  264. Silver et al. (2026b) (opens in a new tab)
  265. Spark Therapeutics Form 8-K (2018) (opens in a new tab)
  266. Spirito et al. (2000) (opens in a new tab)
  267. Stevens-Lapsley et al. (2010) (opens in a new tab)
  268. Stypmann et al. (2006) (opens in a new tab)
  269. Sugie and Nishino (2024) (opens in a new tab)
  270. Sugie et al. (2002) (opens in a new tab)
  271. Sugie et al. (2005) (opens in a new tab)
  272. Sugie et al. (2018) (opens in a new tab)
  273. Takehara et al. (2025) (opens in a new tab)
  274. Tanaka et al. (2000) (opens in a new tab)
  275. Taylor and Adler (2024) (opens in a new tab)
  276. Thakur et al. (2018) (opens in a new tab)
  277. Thompson et al. (2016) (opens in a new tab)
  278. Tice et al. (2023) (opens in a new tab)
  279. Tsuda et al. (2017) (opens in a new tab)
  280. Turner et al. (2025) (opens in a new tab)
  281. Ultragenyx FAYUVI prescribing information (2026) (opens in a new tab)
  282. UnitedHealthcare Genetic Testing for Cardiac Disease medical policy (2026) (opens in a new tab)
  283. Urbich et al. (2020) (opens in a new tab)
  284. Van Der Starre et al. (2013) (opens in a new tab)
  285. Venturiello et al. (2024) (opens in a new tab)
  286. Vertex Pharmaceuticals Form 8-K (2023) (opens in a new tab)
  287. Vilalta (2023) (opens in a new tab)
  288. Vrellaku et al. (2024) (opens in a new tab)
  289. Wei et al. (2021) (opens in a new tab)
  290. Wilde et al. (2022) (opens in a new tab)
  291. Wittlieb-Weber et al. (2015) (opens in a new tab)
  292. Yadin et al. (2022) (opens in a new tab)
  293. Yadin et al. (2023) (opens in a new tab)
  294. Yang et al. (2005) (opens in a new tab)
  295. Yardeni et al. (2017) (opens in a new tab)
  296. Zaki et al. (2013) (opens in a new tab)
  297. Zannad et al. (2010) (opens in a new tab)
  298. Zeppenfeld et al. (2022) (opens in a new tab)
  299. Zhai et al. (2023) (opens in a new tab)
  300. Zhang et al. (2025) (opens in a new tab)